Multiple Myeloma Coverage from Every Angle

Paul G. Richardson, MD, on a New Triplet Therapy in Relapsed/Refractory Multiple Myeloma

Posted: Sunday, June 2, 2019

Paul G. Richardson, MD, of Dana-Farber Cancer Institute, discusses isatuximab, pomalidomide, and dexamethasone as a new treatment option for relapsed/refractory multiple myeloma in light of phase III trial findings comparing the triplet with pomalidomide and dexamethasone.

By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.